source: 
by Timothy Hay
When the Food and Drug Administration told personal-genetics company 23andMe Inc. in November to stop sending consumers detailed information about their DNA, some industry watchers said the move could be a devastating blow to an emerging area of medicine that holds promise for better health outcomes.
But it was more of a flesh wound, said Claremont Creek Ventures Director Ted Driscoll. Though not an investor in 23andMe, he has two genetics-testing companies in his portfolio (Assurerx Health and Natera).
23andMe, a Google-backed startup that offers consumers reams of genetic information after analyzing a saliva sample for $99, may be sidelined for a while, Dr. Driscoll said. But the company will likely rebound after a few tweaks to its business model, and other DNA-testing startups will keep moving forward in the meantime.
Dr. Driscoll talked to VentureWire about the continuing opportunity for investors to get involved in a potentially groundbreaking area of medicine…
Read the full article at the Wall Street Journal